RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has closed the first tranche of the previously announced private placement pursuant to the convertible security funding agreement (the “Agreement”) with Lind Global Macro Fund, LP, a New York based institutional investment fund managed by The Lind Partners, LLC (together, “Lind”) for gross proceeds of CAD$3.5 million (the “First Tranche”).
20210513 – HBP Press Release – Helix_Lind – First Tranche Closing